Bladder medicines in multiple sclerosis: reported benefits alongside cognitive concerns
A systematic review reported improvements in urinary symptoms, quality of life and sleep, while also identifying cognitive problems and other adverse effects.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review reports urinary improvements during antimuscarinic treatment in people with multiple sclerosis, with accompanying improvements in sleep and quality of life. It also reports cognitive problems, dry mouth and dizziness. Because the abstract does not quantify either benefit or harm, it cannot show how these trade-offs balance for an individual.
This abstract-based summary cannot assess which medicines, comparison treatments or follow-up periods drove the results. The abstract provides no effect sizes or adverse-event frequencies, limiting interpretation of both the reported benefits and cognitive concerns.
A question beyond bladder symptoms
The authors searched for clinical evidence about antimuscarinic medicines in multiple sclerosis. Their question covered effects beyond bladder symptoms, including whether urinary improvements accompanied changes in sleep, quality of life or cognition.
Cognitive effects need clearer detail
The review describes cognitive deficits during medicine use, but the abstract does not separate findings by drug or study design. That missing detail prevents a clear comparison of cognitive effects across the treatments reviewed.
The original publication
Antimuscarinics in multiple sclerosis: A systematic review.
Darvishi A, Pakkhesal S, Alipour A et al.
Mult Scler Relat Disord · 2025
- PubMed ID
- 41260079
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.